<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848169</url>
  </required_header>
  <id_info>
    <org_study_id>2018-3716</org_study_id>
    <nct_id>NCT03848169</nct_id>
  </id_info>
  <brief_title>TMD Pulsed Radiofrequency</brief_title>
  <official_title>Pulsed Radiofrequency As A Treatment For Mastecatory Muscle Pain In Temporomandibular Disorder Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRF of the masticatory muscles (masseter, temporalis, medial and lateral pterygoid muscle)&#xD;
      can improve pain intensity and functional recovery of the jaw in patients with&#xD;
      extra-articular TMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The temporomandibular joint is formed by the mandibular condyle inserting into the mandibular&#xD;
      fossa of the temporal bone. Muscles of mastication are primarily responsible for the movement&#xD;
      of this joint. Its functionality may be affected by different disorders that are&#xD;
      characterized by craniofacial pain involving the joint, masticatory muscles, or muscle&#xD;
      innervations of the head and neck. These are known as temporomandibular disorders (TMD). It&#xD;
      affects 10% to 15% of adults, but only 5% seek treatment. The incidence of TMD peaks from 20&#xD;
      to 50 years of age and are more common in female population.&#xD;
&#xD;
      TMD is categorized as intra-articular (within the joint) or extra-articular (involving the&#xD;
      surrounding musculature). Musculoskeletal conditions (myofascial pain disorder) are the most&#xD;
      frequent cause of TMD, accounting for at least 50% of cases. Thus, musculoskeletal conditions&#xD;
      associated with TMD include spasm and/or tenderness to palpation of the masseter, temporalis,&#xD;
      and/or pterygoid muscles.&#xD;
&#xD;
      Etiology of TMD is multifactorial. Factors consistently associated with TMD include other&#xD;
      pain conditions, fibromyalgia, autoimmune disorders, sleep apnea and psychiatric illness.&#xD;
      According to the literature, there is 1.8-fold increase in myofascial pain in people with&#xD;
      anxiety.&#xD;
&#xD;
      It is important to mention that patients with TMD present with an increase risk to develop&#xD;
      chronic and intense headaches. The relationship between chronic TMD and various headaches&#xD;
      could be due to similarity in the pathophysiology of both diseases.4-6 Studies suggest, that&#xD;
      the trigeminal nucleus contribute to central sensitization associated to interference in&#xD;
      descending modulation, and could produce the amplification of pain in this region.&#xD;
&#xD;
      Treatment for TMD is complicated and requires specific knowledge and exercises to strengthen&#xD;
      some groups of muscles and stretch others, occlusal splint therapy, massage, trigger point&#xD;
      injections, and pharmacotherapy. Although the management seems difficult, most of the&#xD;
      patients experience successful improvement once a proper protocol has been established.&#xD;
      Muscle relaxants (baclofen, tizanidin, cyclobenzaprine), nonsteroidal anti-inflammatory drugs&#xD;
      (NSAIDS), opioids, anticonvulsants (e.g., gabapentin), ketamine, tricyclic antidepressants&#xD;
      (e.g., amitriptyline) and benzodiazepines, have also been used clinically for TMD management,&#xD;
      but there is no evidence that supports or refutes the effectiveness of these medications. In&#xD;
      some cases where patients present with severe acute pain, or chronic pain secondary to&#xD;
      serious TMD, inflammation, or degeneration, minimally invasive and invasive procedures should&#xD;
      be considered.&#xD;
&#xD;
      As a general concept, pain treatment by radiofrequency (RF) energy is a technique widely used&#xD;
      in the pain practice. RF denervation is a percutaneous procedure involving the destruction of&#xD;
      nerves using heat generated by a RF current. The basic principles of RF, involve transferring&#xD;
      an alternating electrical current by a generator to a nerve via an active electrode. The&#xD;
      electrode is introduced through an insulated needle, with the exposed active tip transferring&#xD;
      the current to the surrounding tissues.&#xD;
&#xD;
      It is worth mentioning that for interventional pain management purposes there are different&#xD;
      modes of RF that could be used: the continuous RF (CRF) lesion where the heat generated&#xD;
      causes tissue coagulation over 65 degrees Celsius, and the pulsed RF (PRF), which is a&#xD;
      non-destructive procedure where electrical bursts of 20 milliseconds of electricity are&#xD;
      applied followed by 480 milliseconds of no current to allow heat to dissipate, keeping the&#xD;
      tissue temperature below 42 degrees Celsius. Even though different theories have been&#xD;
      suggested for PRF mechanism of action, Vallejo et al. propose that PRF is able to modulate&#xD;
      nerve electrical conduction, and the therapeutic effect is the result of the electrical&#xD;
      field, where c-fos activation and potential effect over the norepinephrine and serotonin&#xD;
      systems have been involved.&#xD;
&#xD;
      Several studies point to a thermal physical effect of PRF for myofascial pain syndrome. It is&#xD;
      proposed, that PRF acts delivering the electric field and heat bursts to the targeted&#xD;
      tissues, without damaging these structures, and blocking the central sensitization and&#xD;
      producing a better response of the downward pathways of pain. So far, several studies have&#xD;
      reported the positive effect of PRF on managing pain syndrome mainly for trapezius muscle and&#xD;
      gastrocnemius.&#xD;
&#xD;
      Tamimi et al, published a case series of PRF treatment for myofascial trigger points and scar&#xD;
      neuromas. They found that 89% of the patients with longstanding myofascial or neuromatous&#xD;
      pain that was refractory to previous treatments, experienced 75-100% reduction in their pain&#xD;
      following PRF management. The researchers also found that 67% of the patients experienced 6&#xD;
      months to greater than one year of pain relief. Despite the small size of the sample, the&#xD;
      authors conclude that PRF could be a minimally invasive, less neurodestructive treatment&#xD;
      modality for these painful conditions.&#xD;
&#xD;
      Taking in consideration previous facts mentioned above and the lack of strong and&#xD;
      high-quality evidence for the use of PRF for extra-articular TMD, there is a specific&#xD;
      interest to develop a prospective pilot study to test the application of this technique into&#xD;
      the main affected muscles that contribute for development of temporomandibular pain. PRF&#xD;
      could be an alternative that might offer an effective way to treat pain in this population&#xD;
      with myofascial origin of pain. Hence, the purpose of this research is to evaluate the&#xD;
      improvement of temporomandibular pain intensity and functionality of the jaw, after&#xD;
      extra-articular PRF in patients with TMD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in static and dynamic TMD pain</measure>
    <time_frame>30 minutes, 4 and 12 weeks post procedure</time_frame>
    <description>using Numerical Rating Scale (NRS) at the end of the procedure (NRS post-procedure), and in the follow-up at 4 weeks and 12 weeks post-procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in maximal mouth opening</measure>
    <time_frame>30 minutes, 4 and 12 weeks post procedure</time_frame>
    <description>by measurement of maximum mouth opening (MMO) in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain medications use</measure>
    <time_frame>30 minutes, 4 and 12 weeks post procedure</time_frame>
    <description>In oral morphine equivalence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lateral jaw excursion</measure>
    <time_frame>30 minutes, 4 and 12 weeks post procedure</time_frame>
    <description>By measurement of lateral jaw excursion in centimetres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in jaw protrusion</measure>
    <time_frame>30 minutes, 4 and 12 weeks post procedure</time_frame>
    <description>By measurement of jaw protrusion in centimetres</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Temporomandibular Joint Pain</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Ultrasound guidance will be used with a high- frequency linear transducer. After the joint has been identified, the researcher will ask the patient to hold his or her mouth in a neutral position. Masseter, temporalis and lateral pterigoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection (mainly over the most common sites of trigger points for the masticatory muscles). Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, an electrode will not be inserted, but a simulation for PRF will be done during 4 minutes for each muscle (sham). At the end of each muscle puncture, 1 ml of local anesthetic (lidocaine 1%) will be injected through the needle, and the needle will be removed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiofrequency</intervention_name>
    <description>See previous page</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Thirty consecutive patients, male and female, between 18 and 80 years old, with&#xD;
             extra-articular TMD as diagnosed by a specialist of the Maxillofacial team based on&#xD;
             Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) for Clinical&#xD;
             and Research Applications, with chronic pain related to TMD (for more than three&#xD;
             months according to IASP definition), and who have plateaued with conventional&#xD;
             treatment in the past three months, will be prospectively recruited at the&#xD;
             Maxillofacial Surgery Clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Patients younger than 18 years old.&#xD;
&#xD;
               -  ASA physical status &gt;3,&#xD;
&#xD;
               -  Contraindication for local anesthetics or RF.&#xD;
&#xD;
               -  Immunosuppression or high risk of infection.&#xD;
&#xD;
               -  Coagulation impairment.&#xD;
&#xD;
               -  Patients with psychiatric illness.&#xD;
&#xD;
               -  Patients with cognitive impairment.&#xD;
&#xD;
               -  Patients currently taking opioids.&#xD;
&#xD;
               -  Patients that had botulinum toxin or steroid injections in the head or neck area&#xD;
                  in the past three months.&#xD;
&#xD;
               -  Patient with pacemaker.&#xD;
&#xD;
               -  Patient with prosthetic joint replacement, or placement of any metallic surgical&#xD;
                  device in or around the area of treatment.&#xD;
&#xD;
               -  Infection of the TMJ.&#xD;
&#xD;
               -  Muscular dystrophy.&#xD;
&#xD;
               -  Pathology or impaired masticatory muscles.&#xD;
&#xD;
               -  Pregnancy.&#xD;
&#xD;
               -  Autoimmune diseases.&#xD;
&#xD;
               -  Arthralgia or intra-articular joint dysfunction.&#xD;
&#xD;
               -  Patients with allergy to Cefazolin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JF Asenjo, MD</last_name>
      <phone>514) 934-1934</phone>
      <phone_ext>43261</phone_ext>
      <email>jfasenjog@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>JF Asenjo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>JF Asenjo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

